Sino Biopharmaceutical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBHMY research report →
Price Chart
About the company
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories.
- CEO
- S. Y. Tse
- IPO
- 2017
- Employees
- 21,435
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on SBHMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.17B
- P/E
- 34.61
- PEG
- -0.85
- P/S
- 2.43
- P/B
- 2.55
- EV/EBITDA
- 7.90
- Div Yield
- 2.22%
- Gross Margin
- 82.43%
- Op Margin
- 29.76%
- Net Margin
- 7.09%
- ROE
- 7.56%
- ROIC
- 12.03%
Latest fiscal year · YoY change
- Revenue
- $30.97B+7.3%
- Gross Profit
- $25.41B+8.0%
- Op Income
- $6.63B
- Net Income
- $2.28B-34.9%
- EPS
- $2.60-35.0%
- OCF Growth
- +40.5%
- FCF Growth
- +45.4%
- 52W High
- $20.16
- 52W Low
- $11.27
- 50D MA
- $13.79
- 200D MA
- $14.63
- Beta
- 0.60
- RSI (14)
- 55
- Avg Volume
- 267
No earnings-call transcripts are available for SBHMY yet.
- Free Float
- 49.3%
- Shares Outstanding
- 888.70M
- Float Shares
- 437.82M
Our SBHMY coverage
Recent articles, reports, and earnings notes.
No research on SBHMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SBHMY report →Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
reuters.com · Jul 8
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal
wsj.com · Jul 7
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
reuters.com · Jul 7
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
reuters.com · Feb 6
Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea
forbes.com · Mar 7
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day
seekingalpha.com · Dec 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.